 |
|
A questionnaire survey on the diagnosis and treatment of Fabry nephropathy in clinical practice
Soo Jeong Choi, Su Hyun Kim, Min Sung Lee, Samel Park, Eunjung Cho, Seung Seok Han, Eun Sil Koh, Byung Ha Chung, Kyung Hwan Jeong, EunHui Bae, Eun Young Lee, Young Joo Kwon
Kidney Res Clin Pract. 2023;42(5):628-638. Published online 2023 Jun 15 DOI: https://doi.org/10.23876/j.krcp.22.235
|
|
Citations to this article as recorded by
 A4GALT-targeting siRNA lipid nanoparticles ameliorate Fabry disease phenotype: Greater efficacy in endothelial cells than in podocytes
Yoo Jin Shin, Hanbi Lee, Xianying Fang, Sheng Cui, Sun Woo Lim, Kang In Lee, Jae Young Lee, Hong Lim Kim, Yuna Oh, Can Li, Chul Woo Yang, Gayeon You, Hyeondo Lee, Hyejung Mok, Byung Ha Chung
Molecular Therapy Nucleic Acids.2025; 36(2): 102573. CrossRef CRISPR/Cas9-mediated suppression of A4GALT rescues endothelial cell dysfunction in a fabry disease vasculopathy model derived from human induced pluripotent stem cells
Yoo Jin Shin, Seung Yun Chae, Hanbi Lee, Xianying Fang, Sheng Cui, Sun Woo Lim, Kang In Lee, Jae Young Lee, Can Li, Chul Woo Yang, Byung Ha Chung
Atherosclerosis.2024; 397: 118549. CrossRef
|